D. Büscher
Board Member
Immunology
Cinfa Biotech
Spain
Biography
Dr. Büscher holds a PhD in Biology, from the University of Hannover, Germany, and obtained an International Executive MBA from the Instituto de Empresa, Madrid. He received his PhD in Immunology, and focused his postdoctoral work at the Salk Institute, La Jolla, California, on molecular developmental biology and stem cell research. In 2004 he joined Cellerix SA, a Madrid-based cell therapy company, and from 2007 on occupied the position of Vice President of R&D. He had been in charge of the preclinical and CMC program of Cellerix, and represented the company in several scientific advices at EMA. Dirk Büscher is inventor on several patents related to stem cell technology. He further has served as industry expert on mesenchymal stem cells in internal EMA workshops In 2010 he accepted a position as chief executive officer of Gri-Cel, a newly created subsidiary of Grifols, Barcelona, dedicated to advanced therapies and innovative therapeutic approaches. He currently serves on two boards of biotech companies, in which Grifols holds a significant participation. Dr. Büscher holds a PhD in Biology, from the University of Hannover, Germany, and obtained an International Executive MBA from the Instituto de Empresa, Madrid. He received his PhD in Immunology, and focused his postdoctoral work at the Salk Institute, La Jolla, California, on molecular developmental biology and stem cell research. In 2004 he joined Cellerix SA, a Madrid-based cell therapy company, and from 2007 on occupied the position of Vice President of R&D. He had been in charge of the preclinical and CMC program of Cellerix, and represented the company in several scientific advices at EMA. Dirk Büscher is inventor on several patents related to stem cell technology. He further has served as industry expert on mesenchymal stem cells in internal EMA workshops In 2010 he accepted a position as chief executive officer of Gri-Cel, a newly created subsidiary of Grifols, Barcelona, dedicated to advanced therapies and innovative therapeutic approaches. He currently serves on two boards of biotech companies, in which Grifols holds a significant participation.
Research Interest
molecular developmental biology and stem cell researc
